Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ViroMed’s CAR-T Therapy Attracts bluebird

This article was originally published in PharmAsia News

Executive Summary

ViroMed has found a global partner to develop immune-oncology cell therapies. It and bluebird bio have reached an agreement worth up to $49m to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed’s proprietary humanized antibody.



Related Companies